HRP20100611T1 - Novi spojevi - Google Patents

Novi spojevi Download PDF

Info

Publication number
HRP20100611T1
HRP20100611T1 HR20100611T HRP20100611T HRP20100611T1 HR P20100611 T1 HRP20100611 T1 HR P20100611T1 HR 20100611 T HR20100611 T HR 20100611T HR P20100611 T HRP20100611 T HR P20100611T HR P20100611 T1 HRP20100611 T1 HR P20100611T1
Authority
HR
Croatia
Prior art keywords
alkyl
pyrazol
ylmethyl
indan
methyl
Prior art date
Application number
HR20100611T
Other languages
English (en)
Croatian (hr)
Inventor
Chhipa Laxmikant
Pukharaj Zambad Shitalkumar
Gupta Ramesh
Tuli Davinder
Kasundra Ashok
Munshi Siralee
Amir Siddiqui M.
Kumar Bhattamisra Subrat
Dutt C.
Chauthaiwale Vijay
Original Assignee
Torrent Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd
Publication of HRP20100611T1 publication Critical patent/HRP20100611T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR20100611T 2007-06-06 2008-06-02 Novi spojevi HRP20100611T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN857KO2007 2007-06-06
PCT/IN2008/000345 WO2008149379A2 (en) 2007-06-06 2008-06-02 Novel compounds

Publications (1)

Publication Number Publication Date
HRP20100611T1 true HRP20100611T1 (hr) 2010-12-31

Family

ID=39828965

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100611T HRP20100611T1 (hr) 2007-06-06 2008-06-02 Novi spojevi

Country Status (26)

Country Link
US (2) US8143424B2 (de)
EP (1) EP2061766B1 (de)
JP (1) JP5243537B2 (de)
KR (1) KR101152965B1 (de)
CN (1) CN101772487B (de)
AR (1) AR066155A1 (de)
AT (1) ATE478053T1 (de)
AU (1) AU2008259314B2 (de)
CA (1) CA2698704C (de)
CY (1) CY1110925T1 (de)
DE (1) DE602008002205D1 (de)
DK (1) DK2061766T3 (de)
EA (1) EA019084B1 (de)
ES (1) ES2351274T3 (de)
HR (1) HRP20100611T1 (de)
IL (1) IL202515A (de)
MX (1) MX2009013070A (de)
NZ (1) NZ582273A (de)
PL (1) PL2061766T3 (de)
PT (1) PT2061766E (de)
RS (1) RS51501B (de)
SI (1) SI2061766T1 (de)
TW (1) TWI360541B (de)
UA (1) UA98962C2 (de)
WO (1) WO2008149379A2 (de)
ZA (1) ZA200908760B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9724381B2 (en) * 2009-05-12 2017-08-08 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
JP5778755B2 (ja) * 2010-04-15 2015-09-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ヒドロキノンの製造方法
EP2566333A4 (de) * 2010-05-07 2014-04-02 Univ Leland Stanford Junior Identifikation von stabilisatoren multimerer proteine
ES2795450T3 (es) 2012-09-17 2020-11-23 Madrigal Pharmaceuticals Inc Procedimiento para sintetizar análogos de hormonas tiroideas y polimorfos de los mismos
EP3417851B1 (de) 2013-09-09 2020-07-22 Peloton Therapeutics, Inc. Arylether und verwendungen davon
CA2931085C (en) 2013-12-16 2021-10-19 Peloton Therapeutics, Inc. Cyclic sulfone and sulfoximine analogs and uses thereof
CN103992225B (zh) * 2014-03-26 2016-01-13 安徽师范大学 一种水杨醛衍生物及其制备方法
US20160045609A1 (en) 2014-08-14 2016-02-18 Mamoun M. Alhamadsheh Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
JP6626885B2 (ja) * 2014-10-31 2019-12-25 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 新しいピリジニルオキシ及びフェニルオキシピラゾリル化合物
US10807948B2 (en) 2015-03-11 2020-10-20 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
US10512626B2 (en) 2015-03-11 2019-12-24 Peloton Therapeautics, Inc. Compositions for use in treating glioblastoma
EP3268362B1 (de) 2015-03-11 2021-10-20 Peloton Therapeutics, Inc. Substituierte pyridine und verwendungen davon
WO2016145032A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
US10335388B2 (en) 2015-04-17 2019-07-02 Peloton Therapeutics, Inc. Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
KR101901556B1 (ko) 2015-11-16 2018-09-21 론자 리미티드 1-메틸-3-(트리플루오로메틸)-1h-피라졸-5-올을 제조하는 방법
RU2621163C1 (ru) * 2016-02-16 2017-05-31 государственное бюджетное образовательное учреждение высшего профессионального образования "Сибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СибГМУ Минздрава России) Антифибролитическое средство
MX394463B (es) 2016-10-18 2025-03-19 Madrigal Pharmaceuticals Inc Métodos para tratar trastornos del hígado o trastornos lipídicos con un agonista de thr-beta.
EP3582773A4 (de) 2017-02-17 2021-03-10 Eidos Therapeutics, Inc. Verfahren zur herstellung von ag-10, dessen zwischenprodukte und salze davon
WO2019183463A1 (en) 2018-03-23 2019-09-26 Eidos Therapeutics, Inc. Methods of treating ttr amyloidosis using ag10
LT3836920T (lt) 2018-08-17 2026-01-26 Eidos Therapeutics, Inc. Ag10 farmacinės formos
SG11202102332QA (en) * 2018-09-22 2021-04-29 Torrent Pharmaceuticals Ltd Methods of producing pyrazole compounds
KR102396602B1 (ko) * 2019-02-28 2022-05-11 주식회사 마더스제약 피라졸 아마이드 유도체 화합물 및 이의 용도
WO2023047203A1 (en) 2021-09-25 2023-03-30 Torrent Pharmaceuticals Ltd Combination of omzotirome and antidiabetic agent, antihypertensive agent or anti-dyslipidemic agent
CN116063296B (zh) * 2021-11-02 2025-08-19 凯思凯迪（上海）医药科技有限公司 一种作为甲状腺激素β受体激动剂的化合物及其用途
EP4482487A4 (de) * 2022-02-23 2026-04-15 Biohaven Therapeutics Ltd Pyrazolylverbindungen als kv7-kanalaktivatoren
WO2023164537A1 (en) * 2022-02-23 2023-08-31 Biohaven Therapeutics Ltd. Pyrazolyl compounds as kv7 channel activators
CN118695860A (zh) * 2022-02-23 2024-09-24 拜奥海芬治疗学有限公司 作为kv7通道激活剂的吡唑基化合物
CN116836158A (zh) * 2022-03-23 2023-10-03 凯思凯迪（上海）医药科技有限公司 一种作为甲状腺激素β受体激动剂的化合物及其用途
CN114920635B (zh) * 2022-04-29 2023-05-12 郑州原理医药研究院有限公司 4-羟基-1-茚酮的制备方法
AR129535A1 (es) 2022-06-21 2024-09-04 Syngenta Crop Protection Ag Derivados de carboxamida heterocíclicos bicíclicos microbiocidas
EP4608836A1 (de) 2022-10-27 2025-09-03 Syngenta Crop Protection AG Mikrobiozide heterobicyclische dihydrooxadiazinderivate
US12377104B1 (en) 2024-02-06 2025-08-05 Madrigal Pharmaceuticals, Inc. Methods for treating a fatty liver disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7598596A (en) 1995-11-01 1997-05-22 Allergan, Inc. Sulfides, sulfoxides and sulfones disubstituted with a tetrahydronaphthalenyl, chromanyl, thiochromanyl or tetrahydroquinolinyl and substituted phenyl or heteroaryl group, having retinoid-like biological activity
PT863136E (pt) 1997-02-25 2004-01-30 Akzo Nobel Nv Derivados de azetidina e de pirrolidina
US6281243B1 (en) * 1998-02-26 2001-08-28 Akzo Nobel N.V. Derivatives of azetidine and pyrrolidine
US6240678B1 (en) 1998-07-09 2001-06-05 Karl Heinz Spether Capping head with torque adjustment
WO2000051971A1 (en) * 1999-03-01 2000-09-08 Pfizer Products Inc. Oxamic acids and derivatives as thyroid receptor ligands
EP1185229A1 (de) 1999-06-01 2002-03-13 University Of Texas Southwestern Medical Center Verfahren zur behandlung von haarausfall
EP1127882A1 (de) * 2000-01-25 2001-08-29 Pfizer Products Inc. Tetrazolverbindungen als Thyroid-Rezeptor-Liganden
US6620830B2 (en) * 2000-04-21 2003-09-16 Pfizer, Inc. Thyroid receptor ligands
DE60232981D1 (de) * 2001-08-17 2009-08-27 Sankyo Agro Co Ltd 3-phenoxy-4-pyridazinolderivat und dieses enthaltende herbizide zusammensetzung
CA2473162A1 (en) * 2002-01-30 2003-08-07 Kissei Pharmaceutical Co., Ltd. Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
WO2003094845A2 (en) * 2002-05-08 2003-11-20 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
US7230025B2 (en) * 2002-09-26 2007-06-12 Pfizer, Inc. Pyrazole derivatives
ITRM20030363A1 (it) 2003-07-24 2005-01-25 Fernando Goglia Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
RU2007148927A (ru) 2005-05-26 2009-07-10 Метабэйзис Терапьютикс, Инк. (Us) Новые тиреомиметики, содержащие фосфиновую кислоту
GB0513692D0 (en) 2005-07-04 2005-08-10 Karobio Ab Novel pharmaceutical compositions
ATE480524T1 (de) 2005-07-21 2010-09-15 Hoffmann La Roche Pyridazinonderivate als schilddrüsenhormon- rezeptoragonisten
CA2620425A1 (en) 2005-08-31 2007-03-08 Bayer Healthcare Llc Anilinopyrazole derivatives useful for the treatment of diabetes

Also Published As

Publication number Publication date
UA98962C2 (ru) 2012-07-10
KR101152965B1 (ko) 2012-06-08
DK2061766T3 (da) 2010-12-13
EA019084B1 (ru) 2014-01-30
EA200901651A1 (ru) 2010-12-30
WO2008149379A3 (en) 2009-03-19
WO2008149379A2 (en) 2008-12-11
CN101772487B (zh) 2014-01-22
TW200911756A (en) 2009-03-16
SI2061766T1 (sl) 2010-12-31
IL202515A0 (en) 2010-06-30
CN101772487A (zh) 2010-07-07
PT2061766E (pt) 2010-11-26
EP2061766B1 (de) 2010-08-18
ES2351274T3 (es) 2011-02-02
US20120202816A1 (en) 2012-08-09
NZ582273A (en) 2011-06-30
CY1110925T1 (el) 2015-06-10
US8143424B2 (en) 2012-03-27
IL202515A (en) 2013-07-31
US20100168110A1 (en) 2010-07-01
KR20100022104A (ko) 2010-02-26
US8378118B2 (en) 2013-02-19
TWI360541B (en) 2012-03-21
JP5243537B2 (ja) 2013-07-24
EP2061766A2 (de) 2009-05-27
AR066155A1 (es) 2009-07-29
MX2009013070A (es) 2010-01-29
ATE478053T1 (de) 2010-09-15
AU2008259314A1 (en) 2008-12-11
CA2698704A1 (en) 2008-12-11
ZA200908760B (en) 2010-08-25
JP2010529108A (ja) 2010-08-26
HK1129221A1 (en) 2009-11-20
CA2698704C (en) 2016-01-19
AU2008259314B2 (en) 2011-05-19
RS51501B (sr) 2011-04-30
PL2061766T3 (pl) 2011-02-28
DE602008002205D1 (de) 2010-09-30

Similar Documents

Publication Publication Date Title
JP5809267B2 (ja) 血漿カリクレイン阻害剤としてのｎ−（（６−アミノ−ピリジン−３−イル）メチル）−ヘテロアリール−カルボキサミド類
US9622991B2 (en) Hematopoietic growth factor mimetic small molecule compounds and their uses
JP2013532713A5 (de)
TWI741377B (zh) 酶抑制劑
ES2325045T3 (es) Nuevos derivados de pirazol heterociclilmetil sustituidos y su uso en el tratamiento de enfermedades cardiovasculares.
KR100413154B1 (ko) 4-(아릴아미노메틸렌)-2,4-디하이드로-3-피라졸론
US7250410B2 (en) Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof
US10781181B2 (en) N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors
JP2009519349A (ja) Ｃｂ２受容体を変調する化合物
KR20120117841A (ko) Ｃｒｔｈ２ 길항제로서의 피라졸 화합물
WO2006071940A2 (en) Enzyme modulators and treatments
JP2010513304A5 (de)
JP2010506950A (ja) 有機化合物
JP2007502287A (ja) メラニン凝集ホルモン受容体アンタゴニスト
JP2007514690A5 (de)
KR20140097459A (ko) 신규 트리플루오로메틸-옥사디아졸 유도체 및 질환의 치료에서의 그의 용도
JP2008507528A (ja) 置換ピラゾール、このような化合物を含有する組成物及び使用方法
JPH11171865A (ja) 縮合ヘテロ環化合物
NZ584573A (en) Heterocyclic compound and pharmaceutical composition thereof
PT2061766E (pt) Novos compostos
US20230265068A1 (en) Transient receptor potential canonical 3 inhibitors and methods of use thereof
BG65858B1 (bg) 1,2-диарилбензимидазоли и фармацевтичното им използване
JP2008516964A5 (de)
JP2004504398A (ja) 抗腫瘍活性を有する２−（１ｈ−インドール−３−イル）−２−オキソ−酢酸アミド
KR20250128366A (ko) 카텝신 l 억제제